Your browser is no longer supported. Please, upgrade your browser.
GNMX Aevi Genomic Medicine, Inc. daily Stock Chart
Aevi Genomic Medicine, Inc.
Index- P/E- EPS (ttm)-1.20 Insider Own0.20% Shs Outstand37.56M Perf Week10.29%
Market Cap72.49M Forward P/E- EPS next Y-1.40 Insider Trans- Shs Float32.10M Perf Month-61.17%
Income-41.90M PEG- EPS next Q-0.27 Inst Own46.30% Short Float3.42% Perf Quarter-63.31%
Sales- P/S- EPS this Y16.00% Inst Trans3.26% Short Ratio1.65 Perf Half Y-65.54%
Book/sh0.94 P/B2.05 EPS next Y-29.50% ROA-88.50% Target Price8.40 Perf Year-56.73%
Cash/sh1.06 P/C1.82 EPS next 5Y- ROE-98.10% 52W Range1.50 - 6.89 Perf YTD-62.74%
Dividend- P/FCF- EPS past 5Y-4.50% ROI- 52W High-71.99% Beta0.91
Dividend %- Quick Ratio7.20 Sales past 5Y- Gross Margin- 52W Low28.67% ATR0.50
Employees24 Current Ratio7.20 Sales Q/Q- Oper. Margin- RSI (14)27.09 Volatility17.92% 11.95%
OptionableYes Debt/Eq0.00 EPS Q/Q-14.60% Profit Margin- Rel Volume2.73 Prev Close1.85
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume666.12K Price1.93
Recom2.20 SMA20-54.31% SMA50-58.07% SMA200-63.44% Volume1,815,655 Change4.32%
Mar-21-17Reiterated Needham Buy $12 → $9
Mar-21-17Downgrade Jefferies Buy → Hold
Mar-28-17 11:00AM  GNMX: SAGA Misses Primary Endpoint But Data Warrants Optimism
Mar-22-17 09:30AM  Today's Research Reports on Stocks to Watch: Pulmatrix and Aevi Genomic Medicine Accesswire
Mar-21-17 06:33AM  Aevi Genomic Medicine downgraded by Jefferies -20.81%
Mar-20-17 01:28PM  Why Aevi Genomic Medicine Got Crushed Today at Motley Fool -59.38%
10:23AM  AEVI GENOMIC MEDICINE, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
07:00AM  Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001 Marketwired
Mar-15-17 08:00AM  Aevi Genomic Medicine to Present at the Oppenheimer 27th Annual Healthcare Conference Marketwired
Mar-14-17 01:04PM  AEVI GENOMIC MEDICINE, INC. Financials -7.25%
Mar-09-17 08:01AM  AEVI GENOMIC MEDICINE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
07:30AM  Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update Marketwired
Feb-27-17 11:53AM  AEVI GENOMIC MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure +7.58%
08:00AM  Aevi Genomic Medicine to Present at the Cowen and Company 37th Annual Health Care Conference Marketwired
Feb-21-17 05:27PM  Aevi Genomic Medicine Announces Expansion of its Collaboration with The Children's Hospital of Philadelphia Marketwired
Feb-15-17 08:00AM  Aevi Genomic Medicine Announces 2017 Investor Day Marketwired
Feb-09-17 08:00AM  Aevi Genomic Medicine to Present at the Leerink Partners 6th Annual Global Healthcare Conference Marketwired
Feb-06-17 12:28PM  [$$] Clinical Development News, Jan. 30-Feb. 3 at The Wall Street Journal
Jan-31-17 08:00AM  Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome Marketwired
Jan-04-17 08:00AM  Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents Marketwired
Dec-23-16 11:40AM  Aevi Genomic Medicine, Inc. :GNMX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 23, 2016
Dec-15-16 08:31AM  AEVI GENOMIC MEDICINE, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Othe
Aevi Genomic Medicine, Inc., a clinical stage medical technology company, engages in the research and development of products in the field of biotechnology and associated medical equipment in the United States. The company develops transduced autologous restorative gene therapy (TARGT), a platform to provide protein and peptide therapies to treat a range of chronic diseases. Its lead product candidate is MDGN-201, which is an endogenous erythropoietin secretion TARGT that is in the Phase I/II clinical trials for the treatment of end stage renal diseases and other indications, including ß-thalassemia. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.